NCT07041112Completed
Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors
Pharmacogenetic Observational Study Evaluating the Influence of Genetic Variants and Cardiometabolic Risk Factors on 10-Year Survival of Biologic Therapies in Patients With Cutaneous Psoriasis With or Without Psoriatic Arthritis
Source: ClinicalTrials.gov · Last updated 27 Jun 2025
Brief summary (registry, in English)
This retrospective observational study aims to evaluate the long-term survival of biologic therapies in adult patients with moderate-to-severe cutaneous psoriasis, with or without psoriatic arthritis, over a period of up to 10 years. The study investigates the influence of clinical, metabolic, and genetic factors, including SNPs and metabolic syndrome components, on treatment durability. Data were obtained from a single-centre cohort treated in routine clinical practice. This analysis seeks to identify predictors of therapeutic response and to explore pharmacogenetic profiles that may inform personalized treatment strategies.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1000 (actual)
- First submitted
- 19 Jun 2025
- Start date
- 1 Jan 2012
- Primary completion date
- 1 Mar 2023
- Lead sponsor
- Juan Ruano Ruiz
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT07041112
What you commit to
- Study type: Observational
- Participants enrolled: 1000
- From 1 Jan 2012 to the primary completion date, 1 Mar 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant participation in interventional clinical trials at baseline.
- Systemic immunosuppressive therapy (e.g., cyclosporine, methotrexate) without biologics during the study period.
Other illness
- Diagnosis of other chronic inflammatory skin diseases (e.g., atopic dermatitis, lupus).
Other
- Patients with incomplete treatment history or missing survival data.
Who the study is looking for
- Adults (≥18 years) diagnosed with moderate-to-severe cutaneous psoriasis.
- Initiation of treatment with a biologic agent between 2010 and 2020.
- Minimum follow-up of 12 months or until drug discontinuation.
- Availability of clinical and treatment data at baseline.
- Availability of at least one blood sample for biomarker/genetic analysis.
- Informed consent obtained for biobanking and genetic analyses.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Dermatology, Reina Sofia University Hospital Coordinator of this site? Confirm its status | Córdoba | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.